This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $708,399.00 to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, to investigate the therapeutic implications of TN BC-specific ETV6 rearrangements, particularly related to chemoresistance and immune evasion. The award began on March 1, 2024 and is scheduled to be completed by February 28, 2027. Hackensack University Medical Center, a non-profit healthcare organization and major research institution, has a history of receiving federal grants for cutting-edge medical research. This project aims to advance the understanding of triple-negative breast cancer and develop new interventions to improve treatment outcomes for this challenging disease.
Generated 11/26/24, 3:47 AM